Rituximab is currently used after the conventional agents have failed in the management of steroid‐dependent (SD)/ steroid‐resistant (SR) podocytopathies and have a safer toxicity profile. We report 53 adults with podocytopathies who were managed effectively with CD19‐targeted rituximab therapy.

中文翻译：

---

利妥昔单抗维持成人足细胞病缓解

利妥昔单抗目前在常规药物治疗类固醇依赖性（SD）/类固醇耐药（SR）足细胞病失败后使用，并且具有更安全的毒性特征。我们报告了 53 名患有足细胞病的成年人，他们通过 CD19 靶向利妥昔单抗治疗得到了有效治疗。